NPPA releases revised maximum retail prices for 543 anti-cancer brands

28 October 2026

The National Pharmaceutical Pricing Authority has released revised Maximum Retail Prices for 543 brands of anti-cancer medicines, with the new prices effective from November 9, 2026. The list is based on what companies submitted up to October 27, 2026 and NPPA says it will be updated on a continual basis as more manufacturers file revised prices. The step follows NPPA's October 17, 2026 decision on Trade Margin Rationalisation for 137 non-scheduled anti-cancer drugs, which include immunotherapy medicines used for over 20 types of cancer, Denosumab, Pegfilgrastim and Bevacizumab. Among the examples given, ANARZOLE (Anastrozole 1 mg, 10 tablets) falls from Rs. 695.76 to Rs. 73.00 and Fulbreca (Fulvestrant 50 mg injection) from Rs. 26,072.16 to Rs. 5,491.00. NPPA works under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers.